top of page

BackTable / Urology / Podcast / Episode #288

Active Surveillance for Intermediate Risk Prostate Cancer

with Dr. Claire de la Calle

When is active surveillance the right choice for intermediate-risk prostate cancer patients? In this episode of BackTable Urology, Dr. Claire de la Calle, Assistant Professor of Urology at the University of Washington, joins Dr. Ruchika Talwar to unpack how active surveillance has evolved beyond low-risk disease and why select Grade Group 2 patients may be appropriate candidates now with thoughtful patient selection.

Be part of the conversation. Put your sponsored messaging on this episode. Learn how.

Active Surveillance for Intermediate Risk Prostate Cancer with Dr. Claire de la Calle on the BackTable Urology Podcast
Ep 288 Active Surveillance for Intermediate Risk Prostate Cancer with Dr. Claire de la Calle
00:00 / 01:04

BackTable, LLC (Producer). (2026, February 3). Ep. 288 – Active Surveillance for Intermediate Risk Prostate Cancer [Audio podcast]. Retrieved from https://www.backtable.com

Stay Up To Date

Follow:

Subscribe:

Sign Up:

Podcast Contributors

Dr. Claire de la Calle on the BackTable Urology Podcast

Dr. Claire de la Calle is a urologist and Assistant Professor of Urology at the University of Washington in Seattle, Washington.

Dr. Ruchika Talwar on the BackTable Urology Podcast

Dr. Ruchika Talwar is a urologic oncologist at Vanderbilt University Medical Center in Nashville, Tennessee.

Synopsis

The conversation explores emerging tools that can refine surveillance decisions, including PSA density, MRI findings, genomic classifiers, and the growing role of AI-assisted pathology. Dr. de la Calle emphasizes the importance of nuanced patient counseling, acknowledging anxiety and long-term risk while reinforcing that time on active surveillance can be a meaningful win when oncologic outcomes remain comparable to upfront treatment.

Timestamps

00:00 - Introduction
02:58 - Current Evidence
05:03 - Patient Selection Criteria
12:11 - Importance of PSA Density and Monitoring Protocols
18:12 - Pathology and Genomic Testing
32:18 - Future Directions and Research
36:33 - Key Takeaways

Resources

ProtecT Trial: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
https://www.nejm.org/doi/full/10.1056/NEJMoa2214122

Canary PASS Study
https://canarypass.org/

Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial
https://pubmed.ncbi.nlm.nih.gov/37137444

The Materials available on BackTable are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

backtable-plus-vi-cta.jpg
Become a BackTable Sponsor

Up Next

Guide to Vaginal Rejuvenation: Myths, Realities & Medical Insights with Dr. Karyn Eilber and Dr. Ariana Smith on the BackTable Urology Podcast
Early Careers in Urology: Strategies for Success with Dr. Raveen Syan and Dr. Helen Hougen on the BackTable Urology Podcast
Updates to Microhematuria Workup Guidelines with Dr. Daniel Barocas on the BackTable Urology Podcast
Shared Decision Making in GU Cancer Management with Dr. Hung-Jui "Ray" Tan on the BackTable Urology Podcast
Understanding Medical Waste Management in Operating Rooms with Dr. Sunil Patel on the BackTable Urology Podcast
Optimizing Bladder Health in BPH Treatment Strategies with Dr. Shawn West on the BackTable Urology Podcast

Articles

Topics

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.

bottom of page